Jushi Holdings Inc. is a vertically-integrated, multi state cannabis operator led by an industry leading management team. In the United States Jushi is focused on building a multi-state portfolio of branded cannabis assets through opportunistic acquisitions, distressed workouts and competitive applications. Jushi strives to maximize shareholder value while delivering high quality products across all levels of the cannabis ecosystem.

Juva Life is working to bring the cannabis market face to face with the sector’s next generation investment grade business model. From in-house research, cultivation, manufacturing, retail, and delivery services, Juva employs state of the art tools in discovery, development, and data science to identify new molecular entities for major unmet medical needs. Our initial focus is on cannabis, where we are deploying our platform to target consumer and pharma applications. Find out more at: https://juvalife.com/.

Komo Plant Based Foods Inc. is a plant-based food company that develops, manufactures, markets and sells a variety of plant-based frozen meals. Komo’s mission is to share the love of plant-based foods through products that are always hearty, satisfying, and made with wholesome ingredients. Its experienced plant-based innovation and development team recreate vegan versions of traditionally cheesy and meaty classics, with 100% plants. Komo's products are sold direct-to-consumer through its eCommerce website and a distribution network of online and brick and mortar grocery, convenience and natural retailer channels. Komo Comfort Foods launched in 2021 with its flagship products: plant-based Lasagna, Shepherd's Pie and Chick'n Pot Pie and has launched a new line of Plant-Based Meal Helpers as a versatile meal starters to allow the creation of many dishes at home.

Levitee Labs is a multidisciplinary integrative wellness company that’s redefining mental healthcare through a preventative, restorative, and transformative approach that includes evidence-based alternative medicines and novel psychedelic therapies. Through a vertically integrated and disciplined M&A model, our core objective is a progressive push towards the introduction of novel treatment modalities, with a key focus on the integration of evidence-based psychedelic medicines and therapies. This model addresses the burden of inefficiencies prevalent within current clinical treatments, particularly those available to underserved patient populations.